| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8440845 | European Journal of Cancer | 2016 | 9 Pages |
Abstract
Neoadjuvant RCT is associated with an increased PD-L1 expression in rectal adenocarcinoma patients, which should prompt clinical trials combining radiotherapy and PD-1/PD-L1 pathway blockade. Combined low PD-L1 expression on tumour and inflammatory cells is an independent negative prognostic marker for OS in RCT of rectal adenocarcinoma.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Markus Hecht, Maike Büttner-Herold, Katharina Erlenbach-Wünsch, Marlen Haderlein, Roland Croner, Robert Grützmann, Arndt Hartmann, Rainer Fietkau, Luitpold V. Distel,